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Purpose or Objective: Radiomics is the high-throughput 
extraction of large amounts of features from radiographic 
images and allows to capture intra-tumoral heterogeneity in 
an non-invasive way. It can therefore have an important role 
in predicting clinical outcome and has the potential to 
support personalized medicine for the treatment of different 
types of cancer. The value of Radiomics has already been 
shown for head-and-neck- and non-small cell lung cancer. In 
this study we assess the prognostic value of CT Radiomics in 
glioblastoma (GBM) patients. 
 
Material and Methods: Clinical data were obtained from 125 
patients with a GBM, diagnosed with a biopsy only and 
treated with radiotherapy +/- TMZ between 2004 and 2015 at 
our institute. Patients underwent pre-treatment CT imaging 
and the tumor volume was manually delineated for treatment 
planning purposes. Pretreatment images from 74 patients 
were available for analysis. In total, 161 Radiomic features 
were extracted, comprising: a) first-order statistics, b) 
shape, and c) (multiscale) texture. Multivariable Cox 
proportional hazards (Cox PH) regression was performed using 
least absolute shrinkage and selection operator (LASSO) 
model selection (100 times 10-fold cross-validated). First, a 
Cox PH model consisting of only clinical features was fitted. 
A second model consisted of both clinical and Radiomic 
features, for which the Radiomic feature space was first 
reduced by selecting cluster medoids after hierarchical 
cluster analysis using correlation (ρ>0.9) as a distance 
measure. Harrell’s concordance index (C-index; 500 times 
bootstrapped) and time dependent AUC curves were used to 
assess model performance. 
 
Results: At a median follow up of 7.4 months, 8 (11%) of the 
patients were still alive at time of analysis. Mean age was 64 
years (20 – 86). WHO performance status was <2 for 82%. 
Sixty-six percent of patients was concurrently treated with 
TMZ. Median overall survival was 6.5 months after treatment. 
The time-dependent AUC curves for the clinical model (C-
index: 0.65) and the model including Radiomics (C-index: 
0.71) are shown in Figure 1, Table 1. Incorporation of 
Radiomic features resulted in an overall higher time-





Conclusion: Radiomics has the potential to predict outcome 
using the pre-treatment CT and possibly identify clinical 
subgroups which can support personalized treatment for 
GBM. Additionally the dataset will be expanded to MR 
imaging, the leading imaging modality in GBM. 
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Purpose or Objective: Arteriovenous malformations (AVMs) 
are the leading causing of intra-cerebral haemorrhage. 
Stereotactic radiosurgery (SRS) is an established treatment 
for arteriovenous malformations (AVM) and commonly 
delivered using Gamma Knife. Linear accelerator (LINAC) SRS 
is often more widely available however there is debate over 
whether if offer equivalent outcomes. The aim of this project 
is to evaluate the outcomes using LINAC SRS for AVMs within 
a large UK neurosciences unit. 
 
Material and Methods: Fifty sequentially treated patients 
with an AVM were identified from a prospective SRS database 
at a tertiary university hospital with a neurosciences unit. 
Planning was performed using BrainLab’s BrainScan 5.3.1 
treatment planning system, utilising a rigid fixed headframe 
and radiographic localisation box to determine target co-
ordinates. Treatment was performed using multiple co-planar 
arcs delivered with a Varian600C linear accelerator at 6MV 
fitted with the BrainLab external stereotactic collimator 
system (fixed cones 10-35mm diameter). A review of all 
imaging was undertaken by a neurovascular radiologist to 
confirm obliteration and post SRS necrosis. A retrospective 
review of case notes was undertaken to confirm toxicity 
which was recorded using CTCAE Version 4. All outcomes 
were correlated prospectively recorded dose metrics. 
 
Results: Forty six patients data analysed with median follow 
up of 5 years (1-14 years).Median age at first SRS treatment 
was 37.5 years (15-71 years) with 24 male and 22 female 
patients. Median lesion volume treated was 1.97cm³ (mean 
2.81cm³ range 0.11-19.50).The median radiosurgery dose was 
19.9Gy (range 13.0 – 28.7). The median normal brain volume 
V12Gy was 5.86cm3 and the median gradient index was 4.4 
(2-9.9). Overall obliteration rate at 3 years was 71.7%. The 
overall incidence of CTCAE v 4 grade 3 or 4 toxicity was 6.5%. 
One patient presented with cognitive and mobility decline 3 
years after treatment and was diagnosed with hydrocephalus. 
One patient had recurrent bi-frontal headaches with nausea 
and vomiting (MRI showed necrosis). One patient had 
refractory epilepsy (parietal AVM) although no imaging 
features present to support necrosis. 
 
Conclusion: LINAC based SRS offers similar outcomes in terms 
of obliteration and toxicity to other platforms. Recent 
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developments in imaging and technology may further improve 
the therapeutic index. 
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Purpose or Objective: Surgery represents the treatment of 
choice for meningiomas. However, complete resection is 
often not possible, and recurrence is common. Radiation 
therapy (RT) can be prescribed as an alternative treatment to 
surgery for low-grade meningiomas, or in the 
recurrent/adjuvant setting. Differentiation between normal 
tissue, i.e. meninges, post-operative changes and residual 
viable tumor can be difficult using MR and CT imaging alone. 
We evaluated the impact of 68Ga-Dotatoc-PET imaging on 
treatment planning including potential benefit in terms of 
outcome. 
 
Material and Methods: We analyzed 15 patients with WHO I 
meningiomas of different localizations. All patients were 
treated with fractionated stereotactic radiotherapy (FSRT) 
with a total dose of 54 Gy and a single dose of 1.8 Gy. An 
advanced radiation oncologist delineated gross tumor volume 
(GTV) independently once based on diagnostic CT and MRI 
only (GTV_MR/CT), and a second time complemented by data 
of diagnostic 68Ga-Dotatoc-PET (GTV_PET). For image fusion 
and target definition BrainLab iPlan RT® software (Munich, 
Germany) was used. The intersection and union volumes of 
both GTVs (GTV_inter, GTV_union), were calculated. 
 
Results: In 11 of 15 patients (73%) the additional data gained 
by 68Ga-Dotatoc-PET led to a lager GTV. In four patients 
(27%) GTV_PET was smaller than GTV_MR/CT. The mean 
intersection of both GTVs was 58.6%. Hence, 41.4% of the 
GTV_PET was contributed only due to information from 68Ga-
Dotatoc-PET. About 22.6% of the GTV_MR/CT was not 
delineated in the GTV_PET volume because no increased 
tracer enhancement could be detected in these parts. Our 
first analyses of overall and progression free survival showed 
no significance in patients with a 68Ga-Dotatoc-PET for 
tumor delineation during treatment planning. 
 
Conclusion: 68Ga-Dotatoc-PET improves the detection of 
residual or recurrent tumor cells especially in patients with 
meningioma of the skull base and the sphenoorbital region. In 
addition it helps to spare normal tissue in patients with large 
tissue defects after operation. However, the interobserver 
variability must be taken into account. The data will now be 
correlated with OS and further analyzed concerning the 
standard uptake values (SUV) of the PET-images to assess if a 
threshold value can be recommended for meningioma 
detection and delineation. 
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Purpose or Objective: The latency, overall extent, and rate, 
of distant brain failure for patients undergoing SRS for 
melanoma brain metastases is not well characterized. We 
evaluated the impact of multiple pre-treatment parameters 
including age, KPS, gender, extracranial disease status (ECD), 
initial number of metastases, initial aggregate tumor volume, 
and B-raf V600E status, on distant brain failure. We also 
evaluated the impact of WBRT performed before, combined 
with, or after SRS. 
 
Material and Methods: The retrospective study population 
included 54 melanoma patients with brain metastases treated 
with SRS between 11/2008 and 01/2014. The distant brain 
metastasis-free survival (DBMFS) was defined as latency in 
months from initial SRS to first subsequent radiographic 
evidence of new brain metastasis. The extent of overall 
distant brain failure (ODBF) was defined as the total number 
of new metastases that developed following initial SRS 
treatment. The distant brain failure rate (DBFR) was defined 
as the ODBF/RFI, where RFI was defined as the maximum 
radiographic follow-up interval in months. Kaplan Meir 
analysis was used to evaluate DBMFS and Log Rank test was 
used to determine the significance (p-value <0.05 was 
considered significant). For ODBF and DBFR, Independent 
sample t-test and one-way ANOVA were used for statistical 
evaluation. 
 
Results: The median overall DBMFS was 5.69 months. A 
significant difference in median DBMFS was observed for 
patients with KPS<70 vs KPS >70 (2.24 vs. 10.44 months, p 
<0.022). Females had significantly worse DBMFS than males 
(5.96 vs. 17.96 months, p<0.009). The initial number of 
metastases, total initial metastasis volume, ECD status, and 
B-raf V600E mutation status, were associated with no 
significant difference in DBMFS. The ODBF was also worse for 
females than males (P<0.002). The DBFR was worse for 
females (p<0.049), and those with c-kit mutation (P<0.024). 
WBRT had no significant effect on DBMFS, ODBF or DBFR in 
the study population. 
 
Conclusion: Characterization of the risk of distant brain 
failure is important to treatment selection, prognosis and 
follow-up. Among patients with melanoma brain metastases 
treated with SRS, our study found that female gender and a 
KPS<70 was associated with a significantly decreased latency 
to distant brain failure. In addition, female gender was 
associated with greater overall number of distant brain 
metastases and rate of distant brain failure. Mutations in c-
kit but not b-raf were found to be associated with increased 
distant brain failure. Further study is underway to examine 
the overall clinical prognostic relevance of these findings. 
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Purpose or Objective: In concern gliosarcoma management, 
the aims of this multicentre retrospective study were to 
identify prognostic or therapeutic factors impacting on 
overall survival. 
 
